Last reviewed · How we verify
T-cell Receptor-engineered T-cells
At a glance
| Generic name | T-cell Receptor-engineered T-cells |
|---|---|
| Also known as | T-cell Receptor-engineered T Cells, T-cell Receptor-engineered T-lymphocytes, TCR T Cells, TCR T-cells, TCR-engineered T-cells |
| Sponsor | Fred Hutchinson Cancer Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Neutrophil count decreased
- Platelet count decreased
- Fatigue
- Lymphocyte count decreased
- Headache
- Nausea
- Anemia
- Vomiting
- White blood cell decreased
- Alanine aminotransferase increased
- White blood cell count decreased
- Aspartate aminotransferase increased
Key clinical trials
- Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation (PHASE1)
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies (PHASE1)
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (PHASE1)
- Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy (PHASE2)
- KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (PHASE1)
- Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer (PHASE2)
- NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (PHASE1)
- T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T-cell Receptor-engineered T-cells CI brief — competitive landscape report
- T-cell Receptor-engineered T-cells updates RSS · CI watch RSS
- Fred Hutchinson Cancer Center portfolio CI